Integra LifeSciences shares drop 17% on revenue miss and probe

Integra LifeSciences (IART) shares dropped 17% after missing Q3 revenue estimates ($410M-$412M vs. $416.3M) and lowering FY26 guidance due to flood damage. The company faces a probe over potential misleading statements. Q4 revenue may be further impacted by $15M-$20M. Insurance is expected to mitigate some losses.

Original reporting
Published Oct 2, 2026, 10:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 4, 2026, 8:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Integra LifeSciences shares drop 17% on revenue miss and probe — source image
Decision brief

The 30-second read

High
01

Why it matters

The combination of a revenue miss, lowered guidance, and legal scrutiny creates immediate downside risk, but insurance recoveries and cash flow strength may cushion long‑term performance.

02

Market read

The news directly impacts IGL's stock price and may influence sentiment toward other med‑tech companies with similar supply‑chain risks.

03

What to watch

Potential upside from cost‑cutting measures and strong cash flow generation not fully reflected in the price decline.

Relevance 8/10Novelty 8/10Timing: intraday today

Background

Integra LifeSciences disclosed a July flood at its Cincinnati plant that reduced Q3 revenue and prompted a $7M impact, leading to a guidance cut and a securities investigation.

Market effects

Medical technology sector may see broader risk reassessment for companies with flood‑related supply chain exposure.

U.S. healthcare stocks could face modest sell pressure.

Limited to U.S. listed med‑tech firms; no immediate global macro effect.

Counterpoint

If insurance recoveries exceed expectations, the earnings impact could be muted, offering a buying opportunity on the dip.

Key entities

  • Stuart Essig

    Chairman and CEO of Integra LifeSciences, discussed recovery plans.

  • SueWallSt

    Notified investors of a pending securities investigation.

Related articles

$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.